AU2017316768B2 - Multivalent vaccine composition - Google Patents

Multivalent vaccine composition Download PDF

Info

Publication number
AU2017316768B2
AU2017316768B2 AU2017316768A AU2017316768A AU2017316768B2 AU 2017316768 B2 AU2017316768 B2 AU 2017316768B2 AU 2017316768 A AU2017316768 A AU 2017316768A AU 2017316768 A AU2017316768 A AU 2017316768A AU 2017316768 B2 AU2017316768 B2 AU 2017316768B2
Authority
AU
Australia
Prior art keywords
amount
present
type
vaccine
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017316768A
Other languages
English (en)
Other versions
AU2017316768A1 (en
Inventor
Rajeev Mhalasakant DHERE
Roger Glass
Baoming Jiang
Ravindra Bapurao KADAM
Abhijeet Sanjeev KAMBLE
Sambhaji Shankar PISAL
Rajendra Narayan SABALE
Jagdish Kamalaji ZADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Centers of Disease Control and Prevention CDC
Original Assignee
Serum Institute of India Pvt Ltd
Centers of Disease Control and Prevention CDC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd, Centers of Disease Control and Prevention CDC filed Critical Serum Institute of India Pvt Ltd
Publication of AU2017316768A1 publication Critical patent/AU2017316768A1/en
Application granted granted Critical
Publication of AU2017316768B2 publication Critical patent/AU2017316768B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017316768A 2016-08-26 2017-08-24 Multivalent vaccine composition Active AU2017316768B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621029037 2016-08-26
IN201621029037 2016-08-26
PCT/IB2017/055100 WO2018037365A1 (en) 2016-08-26 2017-08-24 Multivalent vaccine composition

Publications (2)

Publication Number Publication Date
AU2017316768A1 AU2017316768A1 (en) 2019-04-11
AU2017316768B2 true AU2017316768B2 (en) 2024-04-11

Family

ID=60083359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017316768A Active AU2017316768B2 (en) 2016-08-26 2017-08-24 Multivalent vaccine composition

Country Status (17)

Country Link
US (1) US11235054B2 (https=)
EP (1) EP3503917B1 (https=)
JP (3) JP7384667B2 (https=)
KR (1) KR102607295B1 (https=)
CN (1) CN110691611A (https=)
AU (1) AU2017316768B2 (https=)
CA (1) CA3032901A1 (https=)
CU (1) CU24682B1 (https=)
EA (1) EA201900117A1 (https=)
IL (1) IL264605B2 (https=)
MX (1) MX2019001780A (https=)
MY (1) MY191163A (https=)
PE (1) PE20200004A1 (https=)
PH (1) PH12019500404B1 (https=)
SG (1) SG11201900365WA (https=)
UA (1) UA129115C2 (https=)
WO (1) WO2018037365A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028956A1 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
WO2012093406A2 (en) * 2011-01-05 2012-07-12 Bharat Biotech International Limited A combination heptavalent vaccine
WO2016063291A1 (en) * 2014-10-07 2016-04-28 Serum Institute Of India Private Limited Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
CA2763359C (en) 2009-05-12 2021-07-27 Baoming Jiang New human rotavirus strains and vaccines
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028956A1 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
WO2012093406A2 (en) * 2011-01-05 2012-07-12 Bharat Biotech International Limited A combination heptavalent vaccine
WO2016063291A1 (en) * 2014-10-07 2016-04-28 Serum Institute Of India Private Limited Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jiang, B. et al., 'Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? Evidence from animal studies', Human Vaccines & Immunotherapeutics, (2013-08-08), vol. 9, no. 8, pages 1634 - 1637, doi: 10.4161/hv.24958 *

Also Published As

Publication number Publication date
MX2019001780A (es) 2020-01-13
PH12019500404A1 (en) 2020-01-20
PH12019500404B1 (en) 2024-05-15
JP2021181445A (ja) 2021-11-25
EA201900117A1 (ru) 2019-09-30
BR112019003419A2 (pt) 2019-05-21
AU2017316768A1 (en) 2019-04-11
NZ751127A (en) 2025-08-29
EP3503917B1 (en) 2024-07-03
IL264605B2 (en) 2023-04-01
US11235054B2 (en) 2022-02-01
US20190175722A1 (en) 2019-06-13
WO2018037365A1 (en) 2018-03-01
CU20190013A7 (es) 2019-10-04
JP2024009899A (ja) 2024-01-23
KR20190142311A (ko) 2019-12-26
SG11201900365WA (en) 2019-02-27
UA129115C2 (uk) 2025-01-22
IL264605B (en) 2022-12-01
IL264605A (en) 2019-02-28
CU24682B1 (es) 2023-10-06
EP3503917A1 (en) 2019-07-03
MY191163A (en) 2022-06-03
PE20200004A1 (es) 2020-01-06
JP2019526635A (ja) 2019-09-19
JP7384667B2 (ja) 2023-11-21
CN110691611A (zh) 2020-01-14
WO2018037365A8 (en) 2018-09-20
CA3032901A1 (en) 2018-03-01
KR102607295B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
US8551451B2 (en) Combination vaccine with acellular pertussis
TWI786153B (zh) 具有改善之安定性、增強之免疫原性及降低之反應原性的免疫原性組成物和其製備方法
CN103442730B (zh) 组合七价疫苗
AU2017316768B2 (en) Multivalent vaccine composition
CA2685506A1 (en) Vaccine
CA2963897C (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
RU2504398C2 (ru) Комбинированная вакцина с цельноклеточным коклюшем
TW202038995A (zh) 多價疫苗組合物
BR112019003419B1 (pt) Vacina combinada e processo de fabricação de uma vacina combinada
EA043682B1 (ru) Комбинированная вакцина и способ её производства (варианты)
US20200085940A1 (en) Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
WO2025109417A1 (en) Immunogenic composition of haemophilus influenzae conjugated to protein d
OA21991A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
OA20569A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)